Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 13CNS 3Lymphoid 2Gastrointestinal 2Plasma cell 1Other 1Breast 1

Conditions

Lymphoma, Large-Cell, Anaplastic 2Granuloma, Plasma Cell 1

Interventions

Cyclophosphamide 886Rituximab 864Vincristine 382Etoposide 381fludarabine 342Cytarabine 341Doxorubicin 340fludarabine phosphate 319Methotrexate 310Dexamethasone 283Prednisone 282Lenalidomide 245Filgrastim 228Melphalan 200Peripheral Blood Stem Cell Transplantation 184Radiotherapy 175Whole-Body Irradiation 172Busulfan 165Mycophenolic Acid 161venetoclax 158Bendamustine Hydrochloride 158Granulocyte Colony-Stimulating Factor 151Tacrolimus 145ibrutinib 144Bortezomib 138obinutuzumab 125Gemcitabine 113Cyclosporine 110Antilymphocyte Serum 103Carmustine 100

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × brigatinib × Lymphoid × Clear all
NCT04925609 2025-12-05

Briga-PED

Princess Maxima Center for Pediatric Oncology

Phase 1/2 Recruiting
65 enrolled
LymphoidPlasma cell

Granuloma, Plasma Cell, Lymphoma, Large-Cell, Anaplastic

NCT03719898 2021-01-05

Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma

Fox Chase Cancer Center

Phase 2 Withdrawn
Lymphoid

Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡